Is Eiko Lifescience overvalued or undervalued?

As of 17 October 2025, Eiko Lifescience's valuation grade has moved from fair to expensive, indicating that the company is overvalued. The current PE ratio stands at 38.40, while the EV to EBITDA ratio is 32.90, and the PEG ratio is notably low at 0.62, suggesting potential growth relative to its price. However, these ratios are significantly higher than those of its peers, such as Bajaj Finserv, which has a PE ratio of 34.94 and an EV to EBITDA of 13.02, and Life Insurance, which boasts a much lower PE of 11.49.
In comparison to the broader market, Eiko Lifescience has underperformed, with a year-to-date return of -18.73% against the Sensex's 7.44%. This underperformance, combined with its high valuation ratios, reinforces the conclusion that Eiko Lifescience is overvalued in the current market context.